Pasithea Therapeutics Corp is a biotechnology company focused on the development of innovative therapies for the treatment of psychiatric and neurological disorders
The company is committed to leveraging advanced scientific research and cutting-edge technologies to create new treatment options that address unmet medical needs in these challenging areas. Pasithea aims to improve the quality of life for patients suffering from conditions such as depression and anxiety by exploring novel approaches in drug discovery and development. Through its work, Pasithea seeks to make a meaningful impact on mental health care and enhance overall well-being in affected individuals.
Pasithea Therapeutics reports encouraging early Phase 1 data for PAS-004, showing no adverse events or toxicities. The trial highlights safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11.
Shares of bluebird bio, Inc. (NASDAQBLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
